Margaret Wierman
Concepts (663)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gonadotropin-Releasing Hormone | 41 | 2020 | 208 | 5.310 |
Why?
| Androgens | 17 | 2022 | 174 | 5.270 |
Why?
| Testosterone | 23 | 2023 | 379 | 4.960 |
Why?
| Adrenal Cortex Neoplasms | 11 | 2024 | 61 | 3.700 |
Why?
| Adrenocortical Carcinoma | 12 | 2024 | 64 | 3.600 |
Why?
| Pituitary Neoplasms | 12 | 2024 | 184 | 2.840 |
Why?
| Gonadal Steroid Hormones | 9 | 2020 | 132 | 2.440 |
Why?
| Neurons | 23 | 2020 | 1456 | 2.410 |
Why?
| Endocrinology | 7 | 2016 | 74 | 2.310 |
Why?
| Receptor Protein-Tyrosine Kinases | 9 | 2014 | 221 | 2.190 |
Why?
| Adenoma | 9 | 2018 | 215 | 2.060 |
Why?
| Sexual Dysfunction, Physiological | 6 | 2019 | 67 | 1.980 |
Why?
| Pituitary Gland | 10 | 2018 | 148 | 1.810 |
Why?
| Mitotane | 2 | 2024 | 10 | 1.790 |
Why?
| Hormone Replacement Therapy | 4 | 2022 | 91 | 1.500 |
Why?
| Follicle Stimulating Hormone | 17 | 2024 | 239 | 1.420 |
Why?
| Growth Hormone-Secreting Pituitary Adenoma | 3 | 2017 | 11 | 1.410 |
Why?
| Periodicals as Topic | 5 | 2016 | 206 | 1.390 |
Why?
| Sexual Dysfunctions, Psychological | 3 | 2019 | 34 | 1.370 |
Why?
| Estradiol | 15 | 2024 | 497 | 1.340 |
Why?
| Cell Movement | 12 | 2015 | 939 | 1.330 |
Why?
| Proto-Oncogene Proteins | 10 | 2018 | 634 | 1.310 |
Why?
| Reproduction | 5 | 2011 | 201 | 1.290 |
Why?
| Oncogene Proteins | 6 | 2008 | 52 | 1.290 |
Why?
| Cadherins | 2 | 2024 | 186 | 1.260 |
Why?
| Luteinizing Hormone | 15 | 2023 | 178 | 1.210 |
Why?
| Postmenopause | 8 | 2019 | 370 | 1.180 |
Why?
| Hyperandrogenism | 2 | 2021 | 18 | 1.080 |
Why?
| Dehydroepiandrosterone | 6 | 2022 | 51 | 1.040 |
Why?
| Neuroendocrine Tumors | 2 | 2024 | 99 | 0.990 |
Why?
| Hypogonadism | 6 | 2014 | 83 | 0.990 |
Why?
| Intercellular Signaling Peptides and Proteins | 7 | 2014 | 371 | 0.990 |
Why?
| Adrenal Cortex | 4 | 2020 | 27 | 0.980 |
Why?
| Gene Expression Regulation, Neoplastic | 12 | 2024 | 1353 | 0.960 |
Why?
| Publishing | 3 | 2015 | 141 | 0.950 |
Why?
| ACTH-Secreting Pituitary Adenoma | 1 | 2024 | 11 | 0.910 |
Why?
| Ovary | 8 | 2024 | 214 | 0.880 |
Why?
| Anilides | 1 | 2024 | 73 | 0.870 |
Why?
| Gene Expression Regulation | 14 | 2015 | 2508 | 0.870 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2024 | 813 | 0.860 |
Why?
| Promoter Regions, Genetic | 13 | 2012 | 1200 | 0.860 |
Why?
| Pyridines | 3 | 2024 | 477 | 0.840 |
Why?
| Gonadotrophs | 6 | 2015 | 21 | 0.830 |
Why?
| Humans | 115 | 2024 | 129126 | 0.810 |
Why?
| Consensus | 3 | 2020 | 638 | 0.790 |
Why?
| Hypothalamus | 9 | 2011 | 144 | 0.780 |
Why?
| Societies, Medical | 6 | 2019 | 749 | 0.750 |
Why?
| Animals | 62 | 2024 | 34600 | 0.740 |
Why?
| Anovulation | 1 | 2021 | 8 | 0.730 |
Why?
| Neurosurgical Procedures | 4 | 2020 | 172 | 0.730 |
Why?
| Cell Proliferation | 12 | 2023 | 2347 | 0.710 |
Why?
| Bicycling | 1 | 2021 | 118 | 0.700 |
Why?
| Genes, Tumor Suppressor | 3 | 2017 | 86 | 0.690 |
Why?
| Eunuchism | 1 | 2020 | 3 | 0.680 |
Why?
| Cell Line, Tumor | 12 | 2024 | 3184 | 0.660 |
Why?
| Polycystic Ovary Syndrome | 2 | 2021 | 166 | 0.660 |
Why?
| Estrogens | 7 | 2022 | 354 | 0.650 |
Why?
| Practice Guidelines as Topic | 5 | 2020 | 1493 | 0.640 |
Why?
| Acromegaly | 2 | 2020 | 12 | 0.640 |
Why?
| Mice | 29 | 2024 | 16644 | 0.630 |
Why?
| Sexual Maturation | 4 | 2014 | 52 | 0.630 |
Why?
| Cell Survival | 9 | 2021 | 1077 | 0.610 |
Why?
| Hypopituitarism | 3 | 2014 | 15 | 0.600 |
Why?
| Female | 65 | 2024 | 68517 | 0.600 |
Why?
| Cell Line | 17 | 2015 | 2737 | 0.600 |
Why?
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 33 | 0.570 |
Why?
| Andropause | 2 | 2014 | 5 | 0.560 |
Why?
| Desmosomes | 1 | 2017 | 21 | 0.560 |
Why?
| Quantitative Structure-Activity Relationship | 1 | 2015 | 14 | 0.510 |
Why?
| Receptors, Somatostatin | 1 | 2015 | 24 | 0.500 |
Why?
| Adipocytes | 1 | 2017 | 204 | 0.500 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 71 | 0.490 |
Why?
| Repressor Proteins | 2 | 2015 | 400 | 0.490 |
Why?
| Antibodies | 1 | 2017 | 391 | 0.480 |
Why?
| Erectile Dysfunction | 4 | 1999 | 39 | 0.480 |
Why?
| Premenopause | 4 | 2019 | 128 | 0.470 |
Why?
| Serial Publications | 1 | 2014 | 2 | 0.470 |
Why?
| Chemistry Techniques, Analytical | 1 | 2014 | 19 | 0.470 |
Why?
| Brain Injuries, Traumatic | 1 | 2020 | 341 | 0.470 |
Why?
| Protein Kinase Inhibitors | 3 | 2015 | 872 | 0.460 |
Why?
| Hypothalamo-Hypophyseal System | 3 | 2018 | 177 | 0.460 |
Why?
| Membrane Proteins | 2 | 2019 | 1109 | 0.460 |
Why?
| Signal Transduction | 13 | 2019 | 4838 | 0.450 |
Why?
| Biological Assay | 1 | 2014 | 118 | 0.450 |
Why?
| Human Growth Hormone | 1 | 2014 | 44 | 0.450 |
Why?
| Editorial Policies | 1 | 2014 | 48 | 0.440 |
Why?
| Middle Aged | 30 | 2024 | 31079 | 0.430 |
Why?
| Proto-Oncogene Proteins c-akt | 3 | 2015 | 421 | 0.420 |
Why?
| Histone Deacetylases | 1 | 2015 | 209 | 0.420 |
Why?
| Antineoplastic Agents | 5 | 2024 | 2060 | 0.420 |
Why?
| Diagnostic Techniques, Endocrine | 1 | 2013 | 14 | 0.420 |
Why?
| Cell Cycle Proteins | 2 | 2018 | 580 | 0.410 |
Why?
| Antineoplastic Agents, Hormonal | 2 | 2024 | 161 | 0.410 |
Why?
| Apoptosis | 10 | 2021 | 2438 | 0.410 |
Why?
| Endocrine Glands | 2 | 2010 | 15 | 0.410 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2013 | 74 | 0.400 |
Why?
| Tumor Suppressor Proteins | 4 | 2011 | 313 | 0.400 |
Why?
| Estrogens, Conjugated (USP) | 2 | 2015 | 46 | 0.400 |
Why?
| Vagina | 1 | 2014 | 176 | 0.390 |
Why?
| Dihydrotestosterone | 3 | 2010 | 39 | 0.390 |
Why?
| Male | 47 | 2024 | 63201 | 0.390 |
Why?
| Veterans | 2 | 2023 | 1419 | 0.390 |
Why?
| Antigens, Differentiation | 1 | 2011 | 82 | 0.370 |
Why?
| Pituitary Apoplexy | 1 | 2011 | 1 | 0.370 |
Why?
| Bone Density | 4 | 2020 | 477 | 0.370 |
Why?
| Estrous Cycle | 1 | 2011 | 21 | 0.370 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 148 | 0.360 |
Why?
| Immunohistochemistry | 7 | 2018 | 1671 | 0.360 |
Why?
| Women's Health | 2 | 2019 | 364 | 0.360 |
Why?
| Adult | 27 | 2024 | 35512 | 0.360 |
Why?
| Ovariectomy | 6 | 2024 | 139 | 0.360 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 179 | 0.360 |
Why?
| Estrone | 1 | 2010 | 37 | 0.350 |
Why?
| Models, Molecular | 1 | 2015 | 1483 | 0.350 |
Why?
| Evidence-Based Medicine | 3 | 2014 | 718 | 0.350 |
Why?
| Tetradecanoylphorbol Acetate | 3 | 1996 | 150 | 0.340 |
Why?
| Glycoproteins | 1 | 2012 | 337 | 0.340 |
Why?
| Aged | 19 | 2024 | 22089 | 0.330 |
Why?
| Menstrual Cycle | 1 | 2010 | 124 | 0.330 |
Why?
| Myocardial Infarction | 2 | 2014 | 1014 | 0.330 |
Why?
| Brain Injuries | 3 | 2014 | 468 | 0.330 |
Why?
| Tumor Cells, Cultured | 6 | 2021 | 930 | 0.320 |
Why?
| Trans-Activators | 2 | 2021 | 381 | 0.320 |
Why?
| RNA, Messenger | 14 | 2011 | 2676 | 0.310 |
Why?
| Transcription, Genetic | 6 | 2002 | 1403 | 0.310 |
Why?
| Diagnosis, Differential | 5 | 2021 | 1417 | 0.310 |
Why?
| Rats | 24 | 2024 | 5173 | 0.310 |
Why?
| Kallmann Syndrome | 3 | 2020 | 8 | 0.310 |
Why?
| Stroke | 2 | 2014 | 1067 | 0.300 |
Why?
| Transcriptome | 4 | 2024 | 883 | 0.300 |
Why?
| MAP Kinase Signaling System | 2 | 2018 | 303 | 0.300 |
Why?
| Oligonucleotide Array Sequence Analysis | 4 | 2015 | 757 | 0.280 |
Why?
| Drug Screening Assays, Antitumor | 2 | 2020 | 195 | 0.280 |
Why?
| Medroxyprogesterone | 1 | 2007 | 10 | 0.280 |
Why?
| Oncogene Protein p21(ras) | 1 | 2007 | 16 | 0.280 |
Why?
| Hirsutism | 2 | 2021 | 12 | 0.280 |
Why?
| Biomarkers, Tumor | 3 | 2021 | 1185 | 0.280 |
Why?
| Neurosecretory Systems | 1 | 2007 | 30 | 0.270 |
Why?
| Infertility | 1 | 2007 | 50 | 0.270 |
Why?
| Global Health | 2 | 2019 | 328 | 0.270 |
Why?
| Gene Expression Profiling | 4 | 2024 | 1689 | 0.270 |
Why?
| Proteins | 3 | 2003 | 936 | 0.260 |
Why?
| Neurogenesis | 3 | 2013 | 126 | 0.260 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2014 | 2065 | 0.260 |
Why?
| Liver Neoplasms | 2 | 2023 | 643 | 0.260 |
Why?
| Tumor Microenvironment | 3 | 2020 | 622 | 0.250 |
Why?
| Cell Nucleus | 2 | 2015 | 579 | 0.250 |
Why?
| p38 Mitogen-Activated Protein Kinases | 3 | 2015 | 269 | 0.250 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 431 | 0.250 |
Why?
| Mice, Inbred C57BL | 6 | 2017 | 5284 | 0.250 |
Why?
| Base Sequence | 11 | 2008 | 2135 | 0.250 |
Why?
| Prolactinoma | 2 | 2018 | 12 | 0.250 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 326 | 0.250 |
Why?
| Blood Coagulation | 1 | 2007 | 226 | 0.240 |
Why?
| Mice, Knockout | 4 | 2014 | 2765 | 0.240 |
Why?
| Body Composition | 5 | 2024 | 657 | 0.240 |
Why?
| Amino Acid Transport System y+ | 1 | 2024 | 8 | 0.240 |
Why?
| Transfection | 6 | 2015 | 896 | 0.240 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2007 | 357 | 0.230 |
Why?
| Sulfasalazine | 1 | 2024 | 23 | 0.230 |
Why?
| Drug Repositioning | 1 | 2024 | 25 | 0.230 |
Why?
| Transcription Factors | 4 | 2002 | 1632 | 0.230 |
Why?
| DNA-Binding Proteins | 4 | 2014 | 1423 | 0.230 |
Why?
| Energy Metabolism | 2 | 2024 | 836 | 0.230 |
Why?
| Protein Binding | 5 | 2015 | 2106 | 0.230 |
Why?
| Young Adult | 7 | 2024 | 12389 | 0.220 |
Why?
| DNA | 10 | 2012 | 1392 | 0.220 |
Why?
| Up-Regulation | 4 | 2021 | 828 | 0.220 |
Why?
| Vasodilation | 1 | 2007 | 479 | 0.220 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2002 | 313 | 0.210 |
Why?
| Triamcinolone Acetonide | 1 | 2023 | 27 | 0.210 |
Why?
| Femur Neck | 2 | 2020 | 59 | 0.210 |
Why?
| Rare Diseases | 1 | 2024 | 103 | 0.210 |
Why?
| Models, Biological | 4 | 2012 | 1695 | 0.210 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 2 | 2019 | 129 | 0.210 |
Why?
| Cytoplasm | 2 | 2015 | 258 | 0.210 |
Why?
| Cardiovascular Diseases | 1 | 2015 | 2024 | 0.210 |
Why?
| Rats, Wistar | 1 | 2024 | 398 | 0.200 |
Why?
| Nerve Tissue Proteins | 1 | 2006 | 568 | 0.200 |
Why?
| Wnt Signaling Pathway | 2 | 2021 | 166 | 0.200 |
Why?
| Anorexia | 1 | 2022 | 19 | 0.200 |
Why?
| Double-Blind Method | 4 | 2020 | 1865 | 0.190 |
Why?
| Stress, Physiological | 2 | 2015 | 412 | 0.190 |
Why?
| Genomics | 2 | 2024 | 716 | 0.190 |
Why?
| Myogenic Regulatory Factors | 2 | 2001 | 56 | 0.190 |
Why?
| RNA, Small Interfering | 3 | 2019 | 571 | 0.190 |
Why?
| Disease Models, Animal | 3 | 2020 | 3953 | 0.190 |
Why?
| Retrospective Studies | 9 | 2024 | 14571 | 0.190 |
Why?
| Aldosterone | 2 | 2019 | 42 | 0.190 |
Why?
| Cytoskeletal Proteins | 1 | 2002 | 142 | 0.190 |
Why?
| Sex Hormone-Binding Globulin | 2 | 2019 | 54 | 0.180 |
Why?
| Immunoblotting | 3 | 2018 | 300 | 0.180 |
Why?
| Puberty, Precocious | 5 | 1992 | 14 | 0.180 |
Why?
| Heat-Shock Proteins | 1 | 2002 | 131 | 0.180 |
Why?
| Aurora Kinase A | 1 | 2021 | 55 | 0.180 |
Why?
| Receptors, Somatotropin | 1 | 2020 | 8 | 0.180 |
Why?
| Receptors, Androgen | 1 | 2002 | 143 | 0.180 |
Why?
| Phthalazines | 1 | 2021 | 40 | 0.180 |
Why?
| Cells, Cultured | 7 | 2018 | 4010 | 0.170 |
Why?
| Somatostatin | 1 | 2020 | 54 | 0.170 |
Why?
| Dopamine Agonists | 1 | 2020 | 39 | 0.170 |
Why?
| Pheochromocytoma | 1 | 2021 | 57 | 0.170 |
Why?
| Adrenal Gland Diseases | 1 | 2020 | 6 | 0.170 |
Why?
| Paraganglioma | 1 | 2021 | 49 | 0.170 |
Why?
| Benzamides | 1 | 2021 | 195 | 0.170 |
Why?
| Neoplasm Invasiveness | 3 | 2012 | 480 | 0.170 |
Why?
| Adrenal Cortex Hormones | 1 | 2023 | 519 | 0.160 |
Why?
| Prostatic Neoplasms | 1 | 2007 | 1013 | 0.160 |
Why?
| Radiotherapy | 1 | 2020 | 185 | 0.160 |
Why?
| Receptors, Progesterone | 3 | 2003 | 345 | 0.160 |
Why?
| Transsexualism | 1 | 2019 | 20 | 0.160 |
Why?
| Oncogene Proteins, Fusion | 1 | 2021 | 198 | 0.160 |
Why?
| Hospital Medicine | 1 | 2021 | 91 | 0.160 |
Why?
| Off-Label Use | 1 | 2019 | 51 | 0.160 |
Why?
| Glucose Metabolism Disorders | 1 | 2019 | 11 | 0.160 |
Why?
| Gene Expression | 4 | 2014 | 1462 | 0.160 |
Why?
| Pyrazoles | 2 | 2013 | 405 | 0.160 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2020 | 153 | 0.160 |
Why?
| Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.160 |
Why?
| Pituitary ACTH Hypersecretion | 1 | 2018 | 10 | 0.160 |
Why?
| Lamin Type B | 1 | 2018 | 7 | 0.150 |
Why?
| NIMA-Related Kinases | 1 | 2018 | 8 | 0.150 |
Why?
| Sphenoid Sinus | 1 | 2018 | 8 | 0.150 |
Why?
| Naphthyridines | 1 | 2018 | 15 | 0.150 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 231 | 0.150 |
Why?
| Phosphatidylinositol 3-Kinase | 1 | 2018 | 26 | 0.150 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 181 | 0.150 |
Why?
| Germ-Line Mutation | 2 | 2018 | 138 | 0.150 |
Why?
| Blotting, Northern | 4 | 2000 | 199 | 0.150 |
Why?
| Hyponatremia | 1 | 2018 | 40 | 0.150 |
Why?
| Pilot Projects | 1 | 2023 | 1567 | 0.150 |
Why?
| Calcium-Binding Proteins | 1 | 2019 | 211 | 0.150 |
Why?
| Corticotropin-Releasing Hormone | 1 | 2018 | 61 | 0.140 |
Why?
| Protein Kinase C | 3 | 1995 | 253 | 0.140 |
Why?
| Molecular Sequence Data | 8 | 2000 | 2819 | 0.140 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2020 | 227 | 0.140 |
Why?
| Zebrafish Proteins | 1 | 2020 | 269 | 0.140 |
Why?
| Colorectal Neoplasms | 2 | 2023 | 753 | 0.140 |
Why?
| Recovery of Function | 2 | 2020 | 648 | 0.140 |
Why?
| Gonadotropins | 4 | 2003 | 37 | 0.140 |
Why?
| Gene Deletion | 3 | 2011 | 372 | 0.140 |
Why?
| Thermogenesis | 1 | 2017 | 44 | 0.140 |
Why?
| Prosencephalon | 3 | 2008 | 45 | 0.140 |
Why?
| Parathyroid Neoplasms | 3 | 2003 | 14 | 0.140 |
Why?
| Microarray Analysis | 1 | 2017 | 121 | 0.140 |
Why?
| Exercise | 3 | 2018 | 1950 | 0.140 |
Why?
| Pituitary-Adrenal System | 1 | 2018 | 144 | 0.140 |
Why?
| Homeostasis | 2 | 2018 | 605 | 0.140 |
Why?
| Sleep | 2 | 2020 | 676 | 0.130 |
Why?
| Polymerase Chain Reaction | 4 | 2012 | 1021 | 0.130 |
Why?
| Liver Cirrhosis | 1 | 2019 | 275 | 0.130 |
Why?
| Resistance Training | 2 | 2018 | 153 | 0.130 |
Why?
| Genes, jun | 1 | 1996 | 9 | 0.130 |
Why?
| Transgender Persons | 1 | 2019 | 175 | 0.130 |
Why?
| Genes, fos | 1 | 1996 | 33 | 0.130 |
Why?
| Glycoprotein Hormones, alpha Subunit | 3 | 1990 | 22 | 0.130 |
Why?
| Adiposity | 2 | 2018 | 505 | 0.120 |
Why?
| Binding Sites | 2 | 2015 | 1241 | 0.120 |
Why?
| Non-alcoholic Fatty Liver Disease | 1 | 2019 | 259 | 0.120 |
Why?
| Leuprolide | 1 | 2015 | 19 | 0.120 |
Why?
| Molecular Docking Simulation | 1 | 2015 | 109 | 0.120 |
Why?
| Pituitary Gland, Anterior | 4 | 2007 | 38 | 0.120 |
Why?
| Molecular Conformation | 1 | 2015 | 139 | 0.120 |
Why?
| Treatment Outcome | 5 | 2024 | 10226 | 0.120 |
Why?
| Histone Deacetylase 6 | 1 | 2015 | 19 | 0.120 |
Why?
| Dopamine | 1 | 2018 | 285 | 0.120 |
Why?
| Patient Care Team | 1 | 2020 | 602 | 0.120 |
Why?
| Tumor Stem Cell Assay | 1 | 2015 | 32 | 0.120 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1573 | 0.120 |
Why?
| Testicular Diseases | 1 | 1995 | 7 | 0.120 |
Why?
| Cytoprotection | 1 | 2015 | 50 | 0.120 |
Why?
| Mutant Proteins | 1 | 2015 | 98 | 0.120 |
Why?
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 37 | 0.120 |
Why?
| Contraindications | 1 | 2014 | 88 | 0.120 |
Why?
| Societies, Scientific | 1 | 2014 | 46 | 0.120 |
Why?
| Decision Support Techniques | 1 | 1998 | 405 | 0.110 |
Why?
| Gene Amplification | 1 | 2015 | 103 | 0.110 |
Why?
| Phosphorylation | 3 | 2019 | 1687 | 0.110 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 764 | 0.110 |
Why?
| Hypothyroidism | 1 | 1995 | 71 | 0.110 |
Why?
| Publications | 1 | 2014 | 42 | 0.110 |
Why?
| Reference Standards | 1 | 2014 | 170 | 0.110 |
Why?
| Gene Silencing | 1 | 2015 | 185 | 0.110 |
Why?
| DNA Primers | 3 | 2008 | 510 | 0.110 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2014 | 133 | 0.110 |
Why?
| Catalytic Domain | 1 | 2015 | 217 | 0.110 |
Why?
| Sex Characteristics | 1 | 2019 | 727 | 0.110 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 169 | 0.110 |
Why?
| Cell Hypoxia | 1 | 2015 | 229 | 0.110 |
Why?
| Menopause | 2 | 2007 | 303 | 0.110 |
Why?
| Tubulin | 1 | 2015 | 138 | 0.110 |
Why?
| Blotting, Western | 3 | 2002 | 1169 | 0.110 |
Why?
| Chorionic Gonadotropin | 2 | 2011 | 80 | 0.110 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 1363 | 0.110 |
Why?
| Neoplasm Recurrence, Local | 3 | 2023 | 963 | 0.110 |
Why?
| Adolescent | 6 | 2020 | 20301 | 0.110 |
Why?
| Cytoskeleton | 2 | 2007 | 180 | 0.110 |
Why?
| Receptor Cross-Talk | 1 | 2013 | 21 | 0.110 |
Why?
| Hepatocyte Growth Factor | 1 | 2013 | 33 | 0.110 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 257 | 0.100 |
Why?
| Transcriptional Activation | 2 | 2007 | 356 | 0.100 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2013 | 818 | 0.100 |
Why?
| Indoles | 1 | 2015 | 372 | 0.100 |
Why?
| Pedigree | 1 | 2014 | 486 | 0.100 |
Why?
| Olfactory Pathways | 2 | 2010 | 60 | 0.100 |
Why?
| Patient Readmission | 1 | 2018 | 668 | 0.100 |
Why?
| Professional Practice | 1 | 2013 | 64 | 0.100 |
Why?
| Adrenocorticotropic Hormone | 2 | 2018 | 132 | 0.100 |
Why?
| Aggression | 1 | 2014 | 196 | 0.100 |
Why?
| Testis | 2 | 1990 | 144 | 0.100 |
Why?
| Protein Structure, Tertiary | 1 | 2015 | 836 | 0.100 |
Why?
| G2 Phase | 1 | 2012 | 36 | 0.100 |
Why?
| rac GTP-Binding Proteins | 2 | 2002 | 32 | 0.100 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 1992 | 87 | 0.100 |
Why?
| Triptorelin Pamoate | 3 | 1986 | 19 | 0.100 |
Why?
| Receptors, CCR5 | 1 | 2012 | 58 | 0.100 |
Why?
| Sulfonamides | 1 | 2015 | 500 | 0.100 |
Why?
| Genetic Association Studies | 1 | 2014 | 361 | 0.100 |
Why?
| Cervix Uteri | 1 | 2012 | 51 | 0.100 |
Why?
| Active Transport, Cell Nucleus | 1 | 2012 | 113 | 0.100 |
Why?
| Diagnostic Errors | 1 | 2013 | 160 | 0.100 |
Why?
| Cell Count | 2 | 2011 | 314 | 0.100 |
Why?
| CpG Islands | 1 | 2012 | 152 | 0.090 |
Why?
| Rats, Inbred Strains | 7 | 1990 | 356 | 0.090 |
Why?
| Reference Values | 3 | 2010 | 780 | 0.090 |
Why?
| Pituitary Hormones | 2 | 2008 | 16 | 0.090 |
Why?
| Libido | 2 | 2010 | 24 | 0.090 |
Why?
| Superovulation | 1 | 2011 | 8 | 0.090 |
Why?
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2011 | 10 | 0.090 |
Why?
| Genes, p53 | 1 | 2011 | 70 | 0.090 |
Why?
| Prospective Studies | 1 | 2023 | 7079 | 0.090 |
Why?
| Thyroid Hormones | 2 | 2008 | 54 | 0.090 |
Why?
| Age Factors | 2 | 2014 | 3120 | 0.090 |
Why?
| c-Mer Tyrosine Kinase | 1 | 2011 | 44 | 0.090 |
Why?
| Ki-67 Antigen | 1 | 2011 | 107 | 0.090 |
Why?
| Mice, 129 Strain | 1 | 2011 | 80 | 0.090 |
Why?
| Pituitary Hormone-Releasing Hormones | 2 | 1990 | 10 | 0.090 |
Why?
| Feedback, Physiological | 1 | 2011 | 74 | 0.090 |
Why?
| Kisspeptins | 2 | 2007 | 5 | 0.090 |
Why?
| Integrases | 1 | 2011 | 118 | 0.090 |
Why?
| Precipitin Tests | 2 | 2002 | 93 | 0.090 |
Why?
| Cautery | 1 | 2010 | 4 | 0.090 |
Why?
| Amenorrhea | 2 | 2008 | 28 | 0.090 |
Why?
| Genes, Dominant | 2 | 2020 | 91 | 0.090 |
Why?
| Pituitary Hormones, Anterior | 2 | 2007 | 7 | 0.090 |
Why?
| Sphenoid Bone | 1 | 2010 | 15 | 0.090 |
Why?
| Central Nervous System Cysts | 1 | 2010 | 13 | 0.090 |
Why?
| Mutation | 4 | 2021 | 3700 | 0.090 |
Why?
| Flavonoids | 2 | 2002 | 77 | 0.090 |
Why?
| Aged, 80 and over | 4 | 2019 | 7065 | 0.090 |
Why?
| Quality of Life | 1 | 2022 | 2694 | 0.090 |
Why?
| Cell Division | 1 | 2012 | 779 | 0.090 |
Why?
| Placenta | 2 | 1997 | 716 | 0.080 |
Why?
| Infertility, Male | 1 | 1990 | 61 | 0.080 |
Why?
| Follicle Stimulating Hormone, beta Subunit | 5 | 1990 | 30 | 0.080 |
Why?
| Genes, Retinoblastoma | 2 | 2003 | 8 | 0.080 |
Why?
| Nucleic Acid Hybridization | 5 | 2003 | 188 | 0.080 |
Why?
| Endothelial Cells | 1 | 2014 | 701 | 0.080 |
Why?
| Enzyme Inhibitors | 3 | 2002 | 811 | 0.080 |
Why?
| DNA Damage | 1 | 2011 | 364 | 0.080 |
Why?
| Chromatography, Liquid | 1 | 2010 | 375 | 0.080 |
Why?
| Estrus | 1 | 2008 | 12 | 0.080 |
Why?
| Receptors, G-Protein-Coupled | 2 | 2007 | 206 | 0.080 |
Why?
| Hypoxia | 1 | 2015 | 1035 | 0.080 |
Why?
| Prognosis | 2 | 2019 | 3788 | 0.080 |
Why?
| Cell Adhesion | 2 | 2014 | 445 | 0.080 |
Why?
| Thyrotropin | 3 | 2007 | 109 | 0.080 |
Why?
| Neoplasm Staging | 1 | 2012 | 1293 | 0.070 |
Why?
| Mice, Nude | 2 | 2020 | 683 | 0.070 |
Why?
| Tandem Mass Spectrometry | 1 | 2010 | 451 | 0.070 |
Why?
| Diabetes Complications | 1 | 2010 | 224 | 0.070 |
Why?
| Guidelines as Topic | 1 | 2010 | 261 | 0.070 |
Why?
| Prolactin | 2 | 2007 | 97 | 0.070 |
Why?
| Carcinoma | 2 | 2003 | 214 | 0.070 |
Why?
| Cognition | 2 | 2006 | 1111 | 0.070 |
Why?
| Zebrafish | 2 | 2023 | 464 | 0.070 |
Why?
| Protein Multimerization | 1 | 2008 | 178 | 0.070 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2011 | 508 | 0.070 |
Why?
| Receptors, Steroid | 1 | 2007 | 48 | 0.070 |
Why?
| Cell Line, Transformed | 1 | 2007 | 140 | 0.070 |
Why?
| Carcinoma, Non-Small-Cell Lung | 2 | 2013 | 1046 | 0.070 |
Why?
| Orchiectomy | 5 | 1990 | 65 | 0.070 |
Why?
| Protein Precursors | 1 | 2007 | 126 | 0.070 |
Why?
| Phenotype | 3 | 2020 | 3058 | 0.070 |
Why?
| Research Design | 1 | 2013 | 1040 | 0.070 |
Why?
| Affect | 2 | 2006 | 285 | 0.070 |
Why?
| Mice, Transgenic | 1 | 2011 | 2079 | 0.070 |
Why?
| Models, Neurological | 1 | 2008 | 237 | 0.070 |
Why?
| Bone Morphogenetic Proteins | 1 | 2006 | 129 | 0.060 |
Why?
| Age Determination by Skeleton | 1 | 1986 | 17 | 0.060 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 391 | 0.060 |
Why?
| Tretinoin | 1 | 2006 | 128 | 0.060 |
Why?
| HIV-1 | 1 | 2012 | 842 | 0.060 |
Why?
| Ethanol | 1 | 2010 | 585 | 0.060 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2012 | 1048 | 0.060 |
Why?
| Nerve Net | 1 | 2008 | 257 | 0.060 |
Why?
| Anorexia Nervosa | 1 | 2006 | 75 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 4 | 2015 | 1945 | 0.060 |
Why?
| Blood Coagulation Disorders | 1 | 2007 | 162 | 0.060 |
Why?
| Microscopy, Fluorescence | 2 | 2014 | 402 | 0.060 |
Why?
| Restriction Mapping | 3 | 1995 | 74 | 0.060 |
Why?
| Receptors, Estrogen | 2 | 2002 | 429 | 0.060 |
Why?
| Receptors, LHRH | 1 | 2004 | 14 | 0.060 |
Why?
| Magnetic Resonance Imaging | 3 | 2011 | 3383 | 0.060 |
Why?
| Neoplasms, Hormone-Dependent | 1 | 2004 | 38 | 0.060 |
Why?
| MEF2 Transcription Factors | 2 | 2001 | 62 | 0.060 |
Why?
| Time Factors | 5 | 2019 | 6518 | 0.060 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 940 | 0.060 |
Why?
| Adipose Tissue, White | 1 | 2024 | 38 | 0.060 |
Why?
| Neurites | 1 | 2004 | 46 | 0.060 |
Why?
| Hyperparathyroidism | 1 | 2003 | 13 | 0.060 |
Why?
| Chromosomes, Human, Pair 13 | 1 | 2003 | 14 | 0.050 |
Why?
| Floxuridine | 1 | 2023 | 5 | 0.050 |
Why?
| Genes, BRCA2 | 1 | 2003 | 24 | 0.050 |
Why?
| Hepatic Artery | 1 | 2023 | 58 | 0.050 |
Why?
| DNA Probes | 3 | 1992 | 61 | 0.050 |
Why?
| Polychlorinated Dibenzodioxins | 1 | 2003 | 6 | 0.050 |
Why?
| Databases, Genetic | 1 | 2024 | 228 | 0.050 |
Why?
| Pentobarbital | 1 | 2003 | 15 | 0.050 |
Why?
| Discrimination Learning | 1 | 2003 | 49 | 0.050 |
Why?
| Clinical Trials as Topic | 2 | 2007 | 1000 | 0.050 |
Why?
| ras GTPase-Activating Proteins | 1 | 2002 | 15 | 0.050 |
Why?
| Verbal Learning | 1 | 2003 | 64 | 0.050 |
Why?
| Two-Hybrid System Techniques | 1 | 2002 | 56 | 0.050 |
Why?
| MAP Kinase Kinase 1 | 1 | 2002 | 76 | 0.050 |
Why?
| RNA, Long Noncoding | 1 | 2024 | 178 | 0.050 |
Why?
| HSP27 Heat-Shock Proteins | 1 | 2002 | 10 | 0.050 |
Why?
| rho GTP-Binding Proteins | 1 | 2002 | 62 | 0.050 |
Why?
| COS Cells | 1 | 2002 | 184 | 0.050 |
Why?
| Genes, Reporter | 1 | 2002 | 266 | 0.050 |
Why?
| Reading | 1 | 2003 | 150 | 0.050 |
Why?
| Mental Recall | 1 | 2003 | 184 | 0.050 |
Why?
| Hypnotics and Sedatives | 1 | 2003 | 154 | 0.050 |
Why?
| Androgen Antagonists | 1 | 2002 | 79 | 0.050 |
Why?
| Aurora Kinase B | 1 | 2021 | 8 | 0.050 |
Why?
| Sequence Deletion | 2 | 2002 | 179 | 0.040 |
Why?
| Salaries and Fringe Benefits | 1 | 2021 | 55 | 0.040 |
Why?
| Estrogen Receptor alpha | 1 | 2002 | 134 | 0.040 |
Why?
| Environmental Pollutants | 1 | 2003 | 142 | 0.040 |
Why?
| Precision Medicine | 1 | 2024 | 384 | 0.040 |
Why?
| Receptors, Glucocorticoid | 1 | 2002 | 148 | 0.040 |
Why?
| Molecular Chaperones | 1 | 2002 | 172 | 0.040 |
Why?
| Protein Transport | 1 | 2002 | 422 | 0.040 |
Why?
| Haploinsufficiency | 1 | 2020 | 47 | 0.040 |
Why?
| Caspases | 1 | 2001 | 242 | 0.040 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 323 | 0.040 |
Why?
| Tissue Distribution | 1 | 2000 | 291 | 0.040 |
Why?
| Receptors, Cell Surface | 1 | 2002 | 371 | 0.040 |
Why?
| Adrenal Gland Neoplasms | 1 | 2021 | 83 | 0.040 |
Why?
| beta Catenin | 1 | 2002 | 219 | 0.040 |
Why?
| Drug Synergism | 1 | 2021 | 358 | 0.040 |
Why?
| Body Height | 2 | 1995 | 193 | 0.040 |
Why?
| Ligands | 1 | 2002 | 614 | 0.040 |
Why?
| Indolizines | 1 | 2019 | 4 | 0.040 |
Why?
| Forkhead Box Protein M1 | 1 | 2019 | 6 | 0.040 |
Why?
| Mutagenesis, Site-Directed | 1 | 2000 | 358 | 0.040 |
Why?
| Body Weight | 1 | 2024 | 932 | 0.040 |
Why?
| Cerebellum | 1 | 2001 | 217 | 0.040 |
Why?
| Attention | 1 | 2003 | 437 | 0.040 |
Why?
| Quinoxalines | 1 | 2019 | 65 | 0.040 |
Why?
| Cell Cycle Checkpoints | 1 | 2019 | 95 | 0.040 |
Why?
| Penile Erection | 1 | 1999 | 7 | 0.040 |
Why?
| Progesterone | 2 | 2019 | 244 | 0.040 |
Why?
| Osteoporosis, Postmenopausal | 1 | 2019 | 40 | 0.040 |
Why?
| Bromodeoxyuridine | 1 | 1999 | 77 | 0.040 |
Why?
| Minority Groups | 1 | 2021 | 252 | 0.040 |
Why?
| Actigraphy | 1 | 2019 | 94 | 0.040 |
Why?
| Neoplasms, Experimental | 1 | 2019 | 169 | 0.040 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2019 | 127 | 0.040 |
Why?
| Sequence Homology | 1 | 1998 | 40 | 0.040 |
Why?
| Inappropriate ADH Syndrome | 1 | 2018 | 8 | 0.040 |
Why?
| RNA-Directed DNA Polymerase | 1 | 1998 | 34 | 0.040 |
Why?
| Androstadienes | 1 | 1999 | 107 | 0.040 |
Why?
| Neoplasm Proteins | 1 | 2002 | 421 | 0.040 |
Why?
| Sequence Homology, Nucleic Acid | 2 | 1996 | 150 | 0.040 |
Why?
| Sequence Analysis, RNA | 1 | 2021 | 428 | 0.040 |
Why?
| Gender Identity | 1 | 2019 | 122 | 0.040 |
Why?
| Kinetics | 3 | 1992 | 1617 | 0.040 |
Why?
| Cortisone | 1 | 2018 | 10 | 0.040 |
Why?
| Proof of Concept Study | 1 | 2018 | 65 | 0.040 |
Why?
| Cell Death | 1 | 2020 | 348 | 0.040 |
Why?
| Absorptiometry, Photon | 1 | 2019 | 251 | 0.040 |
Why?
| Academic Medical Centers | 1 | 2021 | 479 | 0.040 |
Why?
| DNA, Complementary | 1 | 1998 | 267 | 0.040 |
Why?
| Disease | 1 | 1999 | 94 | 0.040 |
Why?
| Remission Induction | 1 | 2018 | 271 | 0.040 |
Why?
| MicroRNAs | 1 | 2024 | 677 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2020 | 325 | 0.040 |
Why?
| Faculty, Medical | 1 | 2021 | 266 | 0.040 |
Why?
| Carcinogenesis | 1 | 2019 | 209 | 0.040 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 209 | 0.040 |
Why?
| Hip Joint | 1 | 2019 | 157 | 0.040 |
Why?
| Sirolimus | 1 | 1999 | 189 | 0.040 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2020 | 174 | 0.040 |
Why?
| Postoperative Period | 1 | 2018 | 324 | 0.040 |
Why?
| Octamer Transcription Factor-6 | 1 | 1997 | 1 | 0.030 |
Why?
| Protein-Tyrosine Kinases | 1 | 2000 | 430 | 0.030 |
Why?
| HIV Infections | 1 | 2012 | 2715 | 0.030 |
Why?
| Cell Communication | 1 | 1999 | 299 | 0.030 |
Why?
| Leadership | 1 | 2021 | 357 | 0.030 |
Why?
| Vitamin D | 1 | 2020 | 381 | 0.030 |
Why?
| Mice, Inbred BALB C | 1 | 2020 | 1230 | 0.030 |
Why?
| DNA Footprinting | 1 | 1996 | 33 | 0.030 |
Why?
| Culture Techniques | 1 | 1996 | 81 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 816 | 0.030 |
Why?
| Spodoptera | 1 | 1996 | 37 | 0.030 |
Why?
| Aging | 1 | 2006 | 1772 | 0.030 |
Why?
| Leucine Zippers | 1 | 1996 | 16 | 0.030 |
Why?
| Consensus Sequence | 1 | 1996 | 72 | 0.030 |
Why?
| Cloning, Molecular | 1 | 1997 | 522 | 0.030 |
Why?
| Sequence Alignment | 1 | 1996 | 330 | 0.030 |
Why?
| Pregnancy | 1 | 2008 | 6375 | 0.030 |
Why?
| Hydrocortisone | 1 | 2018 | 304 | 0.030 |
Why?
| Dexamethasone | 1 | 2018 | 340 | 0.030 |
Why?
| Down-Regulation | 1 | 2018 | 634 | 0.030 |
Why?
| Luciferases | 1 | 1996 | 148 | 0.030 |
Why?
| HEK293 Cells | 1 | 2018 | 687 | 0.030 |
Why?
| Transcription Factor AP-1 | 1 | 1996 | 85 | 0.030 |
Why?
| Liver | 1 | 2024 | 1833 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 1998 | 773 | 0.030 |
Why?
| Immunotherapy | 1 | 2020 | 588 | 0.030 |
Why?
| Brain | 2 | 2000 | 2628 | 0.030 |
Why?
| Sexual Behavior | 1 | 2019 | 483 | 0.030 |
Why?
| Self Report | 1 | 2019 | 806 | 0.030 |
Why?
| Adrenal Glands | 2 | 1992 | 71 | 0.030 |
Why?
| Neuropeptides | 1 | 1995 | 72 | 0.030 |
Why?
| E-Selectin | 1 | 2014 | 53 | 0.030 |
Why?
| Enhancer Elements, Genetic | 1 | 1996 | 179 | 0.030 |
Why?
| Immunosuppressive Agents | 1 | 1999 | 690 | 0.030 |
Why?
| Golgi Apparatus | 1 | 2014 | 98 | 0.030 |
Why?
| Dactinomycin | 1 | 1994 | 30 | 0.030 |
Why?
| Half-Life | 1 | 1994 | 144 | 0.030 |
Why?
| Surveys and Questionnaires | 2 | 2019 | 5377 | 0.030 |
Why?
| Loss of Heterozygosity | 2 | 2003 | 46 | 0.030 |
Why?
| Staurosporine | 1 | 1992 | 20 | 0.030 |
Why?
| Alkaloids | 1 | 1992 | 25 | 0.030 |
Why?
| Gonads | 1 | 1992 | 23 | 0.030 |
Why?
| RNA Interference | 1 | 2014 | 441 | 0.030 |
Why?
| Feedback | 2 | 1990 | 159 | 0.030 |
Why?
| Depression, Chemical | 1 | 1992 | 22 | 0.030 |
Why?
| Choriocarcinoma | 1 | 1992 | 9 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2015 | 1013 | 0.020 |
Why?
| DNA Mutational Analysis | 2 | 2003 | 386 | 0.020 |
Why?
| Serum Albumin | 1 | 2013 | 145 | 0.020 |
Why?
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 38 | 0.020 |
Why?
| RNA | 1 | 1998 | 883 | 0.020 |
Why?
| Reactive Oxygen Species | 1 | 2014 | 579 | 0.020 |
Why?
| Mitotic Index | 1 | 2011 | 26 | 0.020 |
Why?
| Cavernous Sinus | 1 | 2011 | 17 | 0.020 |
Why?
| Coronary Angiography | 1 | 2013 | 306 | 0.020 |
Why?
| Puberty | 1 | 1992 | 143 | 0.020 |
Why?
| Mortality | 1 | 2013 | 308 | 0.020 |
Why?
| Peptide Fragments | 2 | 2001 | 686 | 0.020 |
Why?
| Organ Specificity | 1 | 1992 | 291 | 0.020 |
Why?
| Skull Base | 1 | 2011 | 43 | 0.020 |
Why?
| Uterine Neoplasms | 1 | 1992 | 102 | 0.020 |
Why?
| Cohort Studies | 2 | 2013 | 5407 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2012 | 424 | 0.020 |
Why?
| Risk | 1 | 2013 | 856 | 0.020 |
Why?
| HLA-DR Antigens | 1 | 2012 | 225 | 0.020 |
Why?
| Algorithms | 1 | 1998 | 1621 | 0.020 |
Why?
| Ovarian Diseases | 1 | 1990 | 12 | 0.020 |
Why?
| Radiography | 2 | 2011 | 865 | 0.020 |
Why?
| Enzyme Activation | 1 | 1992 | 799 | 0.020 |
Why?
| Body Mass Index | 1 | 2019 | 2266 | 0.020 |
Why?
| Psychomotor Performance | 2 | 2004 | 311 | 0.020 |
Why?
| NF-kappa B | 1 | 2014 | 652 | 0.020 |
Why?
| Ejaculation | 1 | 1990 | 11 | 0.020 |
Why?
| Tumor Burden | 1 | 2011 | 283 | 0.020 |
Why?
| Vaginismus | 1 | 2010 | 1 | 0.020 |
Why?
| Norpregnenes | 1 | 2010 | 3 | 0.020 |
Why?
| Estrogen Receptor Modulators | 1 | 2010 | 17 | 0.020 |
Why?
| Dyspareunia | 1 | 2010 | 8 | 0.020 |
Why?
| Disease Susceptibility | 1 | 2012 | 335 | 0.020 |
Why?
| Injections, Subcutaneous | 1 | 1990 | 145 | 0.020 |
Why?
| Neoplasm Metastasis | 1 | 2012 | 616 | 0.020 |
Why?
| Recombinant Fusion Proteins | 1 | 1992 | 634 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2014 | 1192 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2020 | 5070 | 0.020 |
Why?
| Psychology | 1 | 2010 | 82 | 0.020 |
Why?
| Dehydroepiandrosterone Sulfate | 2 | 1986 | 46 | 0.020 |
Why?
| Rehabilitation Centers | 1 | 2009 | 37 | 0.020 |
Why?
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1988 | 16 | 0.020 |
Why?
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 236 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 221 | 0.020 |
Why?
| Physical Examination | 1 | 2010 | 236 | 0.020 |
Why?
| Protein Biosynthesis | 1 | 1990 | 397 | 0.020 |
Why?
| Receptors, Kisspeptin-1 | 1 | 2007 | 2 | 0.020 |
Why?
| Netrin-1 | 1 | 2007 | 10 | 0.020 |
Why?
| Chemokines, CXC | 1 | 2007 | 68 | 0.020 |
Why?
| Chemokine CXCL12 | 1 | 2007 | 77 | 0.020 |
Why?
| Nerve Growth Factors | 1 | 2007 | 73 | 0.020 |
Why?
| Receptors, CXCR4 | 1 | 2007 | 82 | 0.020 |
Why?
| Coronary Artery Disease | 1 | 2013 | 678 | 0.020 |
Why?
| Rats, Sprague-Dawley | 2 | 2003 | 2245 | 0.020 |
Why?
| Child | 6 | 2010 | 20805 | 0.020 |
Why?
| Postoperative Complications | 1 | 2018 | 2496 | 0.020 |
Why?
| Activities of Daily Living | 1 | 2009 | 389 | 0.020 |
Why?
| Barium Sulfate | 1 | 1985 | 13 | 0.020 |
Why?
| Food, Formulated | 1 | 1985 | 14 | 0.020 |
Why?
| Intestinal Polyps | 1 | 1985 | 17 | 0.020 |
Why?
| Leydig Cells | 1 | 1985 | 13 | 0.020 |
Why?
| Databases, Factual | 1 | 2010 | 1279 | 0.010 |
Why?
| Rectal Neoplasms | 1 | 1985 | 136 | 0.010 |
Why?
| Jaw Neoplasms | 1 | 2003 | 2 | 0.010 |
Why?
| Inflammation | 1 | 2014 | 2668 | 0.010 |
Why?
| Signal Detection, Psychological | 1 | 2003 | 23 | 0.010 |
Why?
| Hormone Antagonists | 1 | 2003 | 30 | 0.010 |
Why?
| Mifepristone | 1 | 2003 | 63 | 0.010 |
Why?
| Radioimmunoassay | 1 | 2003 | 169 | 0.010 |
Why?
| Colonic Neoplasms | 1 | 1985 | 242 | 0.010 |
Why?
| Octamer Transcription Factor-1 | 1 | 2002 | 4 | 0.010 |
Why?
| Syndrome | 1 | 2003 | 337 | 0.010 |
Why?
| Host Cell Factor C1 | 1 | 2002 | 14 | 0.010 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2003 | 51 | 0.010 |
Why?
| Ultrasonography | 1 | 1986 | 724 | 0.010 |
Why?
| Response Elements | 1 | 2002 | 89 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2010 | 2739 | 0.010 |
Why?
| Caspase Inhibitors | 1 | 2001 | 77 | 0.010 |
Why?
| Reaction Time | 1 | 2003 | 409 | 0.010 |
Why?
| Macromolecular Substances | 1 | 2001 | 211 | 0.010 |
Why?
| Extracellular Space | 1 | 2001 | 120 | 0.010 |
Why?
| Potassium | 1 | 2001 | 138 | 0.010 |
Why?
| Analysis of Variance | 1 | 2004 | 1271 | 0.010 |
Why?
| Cross-Over Studies | 1 | 2003 | 513 | 0.010 |
Why?
| Administration, Oral | 1 | 2003 | 759 | 0.010 |
Why?
| Memory, Short-Term | 1 | 2003 | 256 | 0.010 |
Why?
| Lung Neoplasms | 1 | 2013 | 2329 | 0.010 |
Why?
| Protein Isoforms | 1 | 2001 | 379 | 0.010 |
Why?
| Hospitalization | 1 | 2009 | 2077 | 0.010 |
Why?
| Growth Hormone | 2 | 1989 | 96 | 0.010 |
Why?
| Follow-Up Studies | 1 | 1986 | 4915 | 0.010 |
Why?
| Decision Making | 1 | 2003 | 851 | 0.010 |
Why?
| Amino Acid Sequence | 2 | 1990 | 2041 | 0.010 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 1994 | 69 | 0.010 |
Why?
| Retinoblastoma Protein | 1 | 1994 | 54 | 0.010 |
Why?
| Alleles | 1 | 1994 | 845 | 0.010 |
Why?
| Follicular Phase | 1 | 1990 | 40 | 0.010 |
Why?
| Ovulation Induction | 1 | 1990 | 55 | 0.010 |
Why?
| Densitometry | 1 | 1990 | 33 | 0.010 |
Why?
| Child, Preschool | 3 | 1992 | 10450 | 0.010 |
Why?
| Propylthiouracil | 1 | 1989 | 3 | 0.010 |
Why?
| Blotting, Southern | 1 | 1989 | 68 | 0.010 |
Why?
| Triiodothyronine | 1 | 1989 | 44 | 0.000 |
Why?
| Osmolar Concentration | 1 | 1989 | 164 | 0.000 |
Why?
| Molecular Structure | 1 | 1990 | 466 | 0.000 |
Why?
| Introns | 1 | 1989 | 249 | 0.000 |
Why?
| RNA Probes | 1 | 1987 | 13 | 0.000 |
Why?
| Affinity Labels | 1 | 1987 | 25 | 0.000 |
Why?
| Exons | 1 | 1989 | 338 | 0.000 |
Why?
| Biotin | 1 | 1987 | 23 | 0.000 |
Why?
| Azides | 1 | 1987 | 46 | 0.000 |
Why?
| Ovarian Cysts | 1 | 1986 | 7 | 0.000 |
Why?
| Cattle | 1 | 1989 | 962 | 0.000 |
Why?
| Hypothalamic Neoplasms | 1 | 1986 | 9 | 0.000 |
Why?
| Hamartoma | 1 | 1986 | 20 | 0.000 |
Why?
| Bone Development | 1 | 1986 | 49 | 0.000 |
Why?
| Injections, Intravenous | 1 | 1986 | 193 | 0.000 |
Why?
| Adrenal Hyperplasia, Congenital | 1 | 1986 | 37 | 0.000 |
Why?
| Enema | 1 | 1985 | 44 | 0.000 |
Why?
| Uterus | 1 | 1986 | 206 | 0.000 |
Why?
| Insulin-Like Growth Factor I | 1 | 1986 | 307 | 0.000 |
Why?
| Energy Intake | 1 | 1985 | 455 | 0.000 |
Why?
|
|
Wierman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|